Ads
related to: clinical data inc stock symbol
Search results
Results From The WOW.Com Content Network
Medidata Solutions is an American technology company that develops and markets software as a service (SaaS) for clinical trials.These include protocol development, clinical site collaboration and management; randomization and trial supply management; capturing patient data through web forms, mobile health (mHealth) devices, laboratory reports, and imaging systems; quality monitor management ...
Originally named "Clinical Cell Culture" and listed on the ASX under the symbol "C3", the company restructured under the name "Avita Medical" in June 2008. In 2015, the company conducted a strategic divestment of its respiratory business, including the Breath-a-Tech and Funhaler products, to support focus on its regenerative products.
Tuesday, Trinity Biotech plc (NASDAQ:TRIB) stock is trading higher with a session volume of 14.32 million versus the average volume of 118.9K as per data from Benzinga Pro. The company received ...
[28] [29] IMS Health shareholders received 0.384 shares of Quintiles common stock for each share of IMS Health common stock they held, leaving the split of ownership at 51.4% IMS and 48.6% Quintiles. [ 30 ] [ 31 ] The merger was completed in October and the resulting company was a $17.6 billion company called QuintilesIMS. [ 9 ]
As yet unpublished pre-clinical data indicate that Poly-ICR, in combination with a tumor-associated antigen, increases antigen-specific CD8 T-cell levels, while both inducing regression of tumors and preventing tumor growth in mouse models. [4] The company developed Poly-ICR for both internal use and for external licensing opportunities.
January 1996: PPD issues its initial public stock offering and begins trading on the Nasdaq National Market System under the symbol PPDI. October 2005: PPD's board of directors adopts an annual cash dividend policy. July 2009: The company promotes Eshelman to executive chairman and names David Grange chief executive officer. [3]
Context Therapeutics (NASDAQ:CNTX) stock is rising higher on Friday thanks to results from a Phase 0 clinical trial. Source: Shutterstock That trial saw the company treating 10 women suffering ...
In May 2014, Kite Pharma filed a registration with the SEC for an initial public offering (IPO) of its common stock. [45] In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million. [46] [47] [48] The company listed on the NASDAQ Global market under the symbol ...